Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.